Barrington Research Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target decreased by analysts at Barrington Research from $18.00 to $14.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s target price would indicate a potential upside of 27.50% from the stock’s current price. Barrington Research also issued estimates for DENTSPLY SIRONA’s FY2025 earnings at $1.60 EPS, Q3 2026 earnings at $0.38 EPS and Q4 2026 earnings at $0.37 EPS.

Several other analysts also recently weighed in on the stock. Wells Fargo & Company decreased their price target on shares of DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, October 8th. Wall Street Zen lowered DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. JPMorgan Chase & Co. dropped their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Finally, Stifel Nicolaus set a $13.00 price target on DENTSPLY SIRONA in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $16.08.

DENTSPLY SIRONA Stock Performance

XRAY opened at $10.98 on Monday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.69 and a quick ratio of 1.11. The company has a 50 day simple moving average of $12.86 and a two-hundred day simple moving average of $14.45. The firm has a market cap of $2.19 billion, a P/E ratio of -2.32, a PEG ratio of 0.81 and a beta of 1.00. DENTSPLY SIRONA has a 1-year low of $10.69 and a 1-year high of $20.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.08). DENTSPLY SIRONA had a negative net margin of 25.85% and a positive return on equity of 16.33%. The company had revenue of $904.00 million for the quarter, compared to analysts’ expectations of $900.33 million. During the same period in the previous year, the business posted $0.50 earnings per share. The business’s revenue was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. Equities analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XRAY. Vanguard Group Inc. raised its stake in DENTSPLY SIRONA by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock valued at $279,263,000 after acquiring an additional 869,566 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of DENTSPLY SIRONA by 11.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier’s stock worth $208,590,000 after buying an additional 1,412,517 shares during the period. AQR Capital Management LLC increased its position in shares of DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in shares of DENTSPLY SIRONA by 4.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier’s stock valued at $180,445,000 after acquiring an additional 538,531 shares during the period. Finally, Lazard Asset Management LLC raised its stake in DENTSPLY SIRONA by 8.0% during the 2nd quarter. Lazard Asset Management LLC now owns 10,107,657 shares of the medical instruments supplier’s stock worth $160,508,000 after buying an additional 745,421 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.